ArticlePloS one2026
Burden of head and neck cancers in five East Asian countries from 1990 to 2023: Observation, comparison, and forecast from the global burden of disease study 2023.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck cancer (HNC) poses a significant public health challenge worldwide, yet the long-term trends and heterogeneity of its burden within East Asia remain inadequately characterized. This study aims to provide a comprehensive assessment of the HNC burden in five East Asian countries from 1990 to 2023 and project future trends.
methodsUtilizing data from the Global Burden of Disease (GBD) 2023, we analyzed the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of HNC in China, Japan, the Republic of Korea, the Democratic People's Republic (DPR) of Korea, and Mongolia. We employed a comprehensive analytical approach encompassing age-standardized rates, temporal trends, Joinpoint regression, risk factor attribution, age-period-cohort analysis, as well as decomposition and forecasting analyses.
resultsFrom 1990 to 2023, substantial heterogeneity was observed. China demonstrated significant declines in age-standardized incidence rate (ASIR) and mortality rate (ASMR). Conversely, Japan experienced concerning increases in ASIR and ASMR. The Republic of Korea maintained a stable ASIR while achieving a marked ASMR reduction. The Democratic People's Republic of Korea showed increases in both ASIR and ASMR, while Mongolia reported declines in ASIR and ASMR. Age distribution shifted markedly towards older populations in China, Japan, and the Republic of Korea. Smoking remained the predominant risk factor across HNC subtypes. Forecasts to 2038 project a continued rise in ASIR for Japan and the DPR of Korea, and a high ASMR for the DPR of Korea.
conclusionThe HNC burden in East Asia exhibits divergent national trajectories, with smoking remaining the predominant attributable risk factor. Further research is needed to elucidate underlying causes of these cross-country disparities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.